Three paclitaxel molecules linked by a cleavable succinyl ester linkage to a brain peptide vector, Angiopep-2, conjugate named ANG1005.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Digoxin | Digoxin may decrease the cardiotoxic activities of Paclitaxel trevatide. |
| Acetyldigitoxin | Acetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel trevatide. |
| Deslanoside | Deslanoside may decrease the cardiotoxic activities of Paclitaxel trevatide. |
| Ouabain | Ouabain may decrease the cardiotoxic activities of Paclitaxel trevatide. |
| Digitoxin | Digitoxin may decrease the cardiotoxic activities of Paclitaxel trevatide. |
| Oleandrin | Oleandrin may decrease the cardiotoxic activities of Paclitaxel trevatide. |
| Cymarin | Cymarin may decrease the cardiotoxic activities of Paclitaxel trevatide. |
| Proscillaridin | Proscillaridin may decrease the cardiotoxic activities of Paclitaxel trevatide. |
| Metildigoxin | Metildigoxin may decrease the cardiotoxic activities of Paclitaxel trevatide. |
| Lanatoside C | Lanatoside C may decrease the cardiotoxic activities of Paclitaxel trevatide. |
| Gitoformate | Gitoformate may decrease the cardiotoxic activities of Paclitaxel trevatide. |
| Acetyldigoxin | Acetyldigoxin may decrease the cardiotoxic activities of Paclitaxel trevatide. |
| Peruvoside | Peruvoside may decrease the cardiotoxic activities of Paclitaxel trevatide. |
| Peginterferon alfa-2a | The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Paclitaxel trevatide. |
| Trastuzumab | The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Paclitaxel trevatide. |
| Bevacizumab | The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel trevatide. |
| Bortezomib | The risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Paclitaxel trevatide. |
| Cladribine | The risk or severity of cardiotoxicity can be increased when Cladribine is combined with Paclitaxel trevatide. |
| Carmustine | The risk or severity of cardiotoxicity can be increased when Carmustine is combined with Paclitaxel trevatide. |
| Amsacrine | The risk or severity of cardiotoxicity can be increased when Amsacrine is combined with Paclitaxel trevatide. |
| Bleomycin | The risk or severity of cardiotoxicity can be increased when Bleomycin is combined with Paclitaxel trevatide. |
| Mitomycin | The risk or severity of cardiotoxicity can be increased when Mitomycin is combined with Paclitaxel trevatide. |
| Vindesine | The risk or severity of cardiotoxicity can be increased when Vindesine is combined with Paclitaxel trevatide. |
| Vinorelbine | The risk or severity of cardiotoxicity can be increased when Vinorelbine is combined with Paclitaxel trevatide. |
| Teniposide | The risk or severity of cardiotoxicity can be increased when Teniposide is combined with Paclitaxel trevatide. |
| Epirubicin | The risk or severity of cardiotoxicity can be increased when Epirubicin is combined with Paclitaxel trevatide. |
| Cisplatin | The risk or severity of cardiotoxicity can be increased when Cisplatin is combined with Paclitaxel trevatide. |
| Cyclophosphamide | The risk or severity of cardiotoxicity can be increased when Cyclophosphamide is combined with Paclitaxel trevatide. |
| Vincristine | The risk or severity of cardiotoxicity can be increased when Vincristine is combined with Paclitaxel trevatide. |
| Fluorouracil | The risk or severity of cardiotoxicity can be increased when Fluorouracil is combined with Paclitaxel trevatide. |
| Pentostatin | The risk or severity of cardiotoxicity can be increased when Pentostatin is combined with Paclitaxel trevatide. |
| Methotrexate | The risk or severity of cardiotoxicity can be increased when Methotrexate is combined with Paclitaxel trevatide. |
| Vinblastine | The risk or severity of cardiotoxicity can be increased when Vinblastine is combined with Paclitaxel trevatide. |
| Imatinib | The risk or severity of cardiotoxicity can be increased when Imatinib is combined with Paclitaxel trevatide. |
| Tamoxifen | The risk or severity of cardiotoxicity can be increased when Tamoxifen is combined with Paclitaxel trevatide. |
| Daunorubicin | The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Paclitaxel trevatide. |
| Tretinoin | The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Paclitaxel trevatide. |
| Etoposide | The risk or severity of cardiotoxicity can be increased when Etoposide is combined with Paclitaxel trevatide. |
| Mechlorethamine | The risk or severity of cardiotoxicity can be increased when Mechlorethamine is combined with Paclitaxel trevatide. |
| Doxorubicin | The risk or severity of cardiotoxicity can be increased when Doxorubicin is combined with Paclitaxel trevatide. |
| Busulfan | The risk or severity of cardiotoxicity can be increased when Busulfan is combined with Paclitaxel trevatide. |
| Thalidomide | The risk or severity of cardiotoxicity can be increased when Thalidomide is combined with Paclitaxel trevatide. |
| Fludarabine | The risk or severity of cardiotoxicity can be increased when Fludarabine is combined with Paclitaxel trevatide. |
| Capecitabine | The risk or severity of cardiotoxicity can be increased when Capecitabine is combined with Paclitaxel trevatide. |
| Arsenic trioxide | The risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Paclitaxel trevatide. |
| Idarubicin | The risk or severity of cardiotoxicity can be increased when Idarubicin is combined with Paclitaxel trevatide. |
| Ifosfamide | The risk or severity of cardiotoxicity can be increased when Ifosfamide is combined with Paclitaxel trevatide. |
| Mitoxantrone | The risk or severity of cardiotoxicity can be increased when Mitoxantrone is combined with Paclitaxel trevatide. |
| Anastrozole | The risk or severity of cardiotoxicity can be increased when Anastrozole is combined with Paclitaxel trevatide. |
| Paclitaxel | The risk or severity of cardiotoxicity can be increased when Paclitaxel is combined with Paclitaxel trevatide. |
| Docetaxel | The risk or severity of cardiotoxicity can be increased when Docetaxel is combined with Paclitaxel trevatide. |
| Aldoxorubicin | The risk or severity of cardiotoxicity can be increased when Aldoxorubicin is combined with Paclitaxel trevatide. |
| Cabazitaxel | The risk or severity of cardiotoxicity can be increased when Paclitaxel trevatide is combined with Cabazitaxel. |
| Paclitaxel poliglumex | The risk or severity of cardiotoxicity can be increased when Paclitaxel trevatide is combined with Paclitaxel poliglumex. |
| Pertuzumab | The risk or severity of cardiotoxicity can be increased when Paclitaxel trevatide is combined with Pertuzumab. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Paclitaxel trevatide. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Paclitaxel trevatide. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Paclitaxel trevatide. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Paclitaxel trevatide. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Quinisocaine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Paclitaxel trevatide. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Paclitaxel trevatide is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Paclitaxel trevatide is combined with Etrasimod. |